Comparing Single- Vs Multi-Fraction Spine Stereotactic Radiosurgery in Spinal Metastases

This study is comparing two ways of giving radiation therapy for spinal metastases (cancer that has spread to the spine). You would receive either a single treatment of 22 Gy (gray, a unit of radiation dose) called single-fraction spine SRS, or two treatments of 14 Gy each (totaling 28 Gy) called multi-fraction spine SRS. The main goal is to see if multi-fraction SRS is better at controlling the tumor in your spine after one year. To join, you must be at least 18 years old and have 1 to 3 spinal tumors that need treatment. The current status of this study is unclear.

Study design: This study is designed to enroll 274 participants. You would be randomly assigned to one of two treatment groups.
What's involved: Not specified in the trial record.
Compensation: Not stated in the trial record.
Follow-up: Your tumor control will be measured at 1 year after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Comparing SingLe- Vs Multi-Fraction Spine STereotActic Radiosurgery in Spinal Metastases

Recruiting

PHASE3Ages 18+InterventionalTreatment

Stanford University

~274 participants

Updated 2026-07-27 on ClinicalTrials.gov

What's tested:Single-fraction spine SRSMulti-fraction spine SRS

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Tumor control

Measured over 1 year

Conditions

Spinal Metastases

NCT06173401

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

Stanford University School of Medicine
Palo Alto, Californiastudy coordinator listed
Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

Erqi Pollom, MD · PRINCIPAL_INVESTIGATOR · Stanford University

Who to contact

Kelly Huang

[email protected]

650-724-4606

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Histologically, cytologically, or radiographically confirmed diagnosis of metastatic cancer Age ≥ 18 years

Patients who have cervical, thoracic, or lumbar spine metastasis that need treatment.

Patients will have 1 to 3 separate spinal sites that require treatment.

Each spinal site to be treated on trial will span 1-2 contiguous vertebral levels

ECOG 0-2

Negative serum or urine pregnancy test within 14 days prior to enrollment for people of childbearing potential or who are not postmenopausal

people of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control

Ability to understand and the willingness to sign (personally or by a legal authorized representative) the written IRB approved informed consent document

Exclusion

Prior or planned radiation off study within or overlapping with study treatment site

Inability to have either an MRI or a CT scan. Patients with pacemaker will be allowed to undergo CT instead of MRI

Pediatric patients (age \<18 years old), pregnant women, and nursing patients will be excluded

Histology's of myeloma or lymphoma

Patients with strength 1-3 (of 5), bladder incontinence, bowel incontinence, and/or bladder retention that is associated with spinal site to be treated

Prior surgery to spinal site intended to be treated with protocol SRS

Excluded those with SINS 13-18

What this trial measures

Tumor control1 year
To determine whether fractionated Stereotactic Radiosurgery (SRS) for spine metastases is associated with improved local tumor control at 1 year following SRS compared to single-fraction SRS.

Trialytics